Provided by Tiger Fintech (Singapore) Pte. Ltd.

Evaxion Biotech A/S

2.45
-0.1350-5.22%
Volume:47.54K
Turnover:122.58K
Market Cap:15.48M
PE:-0.41
High:2.69
Open:2.61
Low:2.43
Close:2.59
Loading ...

Evaxion Announces Business Update and First Quarter 2025 Financial Results

THOMSON REUTERS
·
27 May

Evaxion Biotech Q1 Pretax Profit USD -1.772 Million

THOMSON REUTERS
·
27 May

Evaxion a/S - Current Cash at Hand Sufficient to Fund Operations Until Mid-2026

THOMSON REUTERS
·
27 May

Evaxion A/S expected to post a loss of 65 cents a share - Earnings Preview

Reuters
·
23 May

European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading

MT Newswires Live
·
22 May

Evaxion Begins Extension of Phase 2 Trial for AI-Designed Cancer Vaccine

TIPRANKS
·
22 May

Evaxion Biotech Doses First Patient in Extension of Cancer Vaccine Trial

MT Newswires Live
·
22 May

BRIEF-Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

Reuters
·
22 May

Evaxion Biotech doses first patient in extension of phase 2 trial on EVX-01

TIPRANKS
·
22 May

Evaxion Doses First Patient in Extension of Phase 2 Trial Exploring the Full Potential of AI-Designed Personalized Cancer Vaccine Evx-01

THOMSON REUTERS
·
22 May

Evaxion a/S - Trial on Track for Two-Year Data Readout in H2 2025

THOMSON REUTERS
·
22 May

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires Live
·
15 May

European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading

MT Newswires Live
·
13 May

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live
·
12 May

Evaxion Biotech a/S - Ongoing Phase 2 Trial With Evx-01 on Track for Two-Year Data Readout in H2, 2025

THOMSON REUTERS
·
28 Apr

80% of the Evx-01 Vaccine Targets Trigger a Tumor-Reactive Immune Response - Evaxion Presents Striking Evx-01 Data at the Aacr Annual Meeting

THOMSON REUTERS
·
28 Apr

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

GlobeNewswire
·
28 Apr

EVAX Provided Great Cancer Vaccine Update

Zacks Small Cap Research
·
28 Apr

Evaxion to present at World Vaccine Congress

GlobeNewswire
·
10 Apr

European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading

MT Newswires Live
·
07 Apr